Financial Counselors Inc. Grows Position in Stryker Co. (NYSE:SYK)

Financial Counselors Inc. boosted its stake in shares of Stryker Co. (NYSE:SYK) by 4.3% during the 3rd quarter, Holdings Channel.com reports. The firm owned 38,370 shares of the medical technology company’s stock after buying an additional 1,593 shares during the quarter. Financial Counselors Inc.’s holdings in Stryker were worth $13,862,000 as of its most recent filing with the SEC.

Other institutional investors and hedge funds also recently bought and sold shares of the company. Kennedy Capital Management LLC bought a new stake in Stryker during the first quarter valued at about $957,000. Swedbank AB bought a new stake in Stryker during the first quarter valued at about $16,239,000. Atria Investments Inc raised its holdings in Stryker by 12.2% during the first quarter. Atria Investments Inc now owns 20,395 shares of the medical technology company’s stock valued at $7,299,000 after acquiring an additional 2,212 shares during the period. PGGM Investments raised its holdings in Stryker by 11.0% during the first quarter. PGGM Investments now owns 6,864 shares of the medical technology company’s stock valued at $2,456,000 after acquiring an additional 680 shares during the period. Finally, Invst LLC raised its holdings in Stryker by 4.4% during the first quarter. Invst LLC now owns 1,252 shares of the medical technology company’s stock valued at $444,000 after acquiring an additional 53 shares during the period. 77.09% of the stock is currently owned by hedge funds and other institutional investors.

Insider Activity

In related news, CEO Kevin Lobo sold 57,313 shares of the stock in a transaction that occurred on Thursday, November 7th. The stock was sold at an average price of $368.70, for a total value of $21,131,303.10. Following the transaction, the chief executive officer now owns 100,027 shares of the company’s stock, valued at $36,879,954.90. This represents a 36.43 % decrease in their ownership of the stock. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is available through the SEC website. Also, VP M Kathryn Fink sold 2,121 shares of the stock in a transaction that occurred on Friday, September 13th. The stock was sold at an average price of $370.00, for a total value of $784,770.00. Following the completion of the transaction, the vice president now directly owns 10,042 shares in the company, valued at approximately $3,715,540. This trade represents a 17.44 % decrease in their position. The disclosure for this sale can be found here. Over the last 90 days, insiders have sold 66,781 shares of company stock valued at $24,612,275. 5.90% of the stock is currently owned by insiders.

Analysts Set New Price Targets

A number of equities research analysts have commented on SYK shares. JPMorgan Chase & Co. raised their price target on Stryker from $375.00 to $420.00 and gave the company an “overweight” rating in a report on Wednesday, October 30th. BTIG Research boosted their target price on Stryker from $383.00 to $394.00 and gave the stock a “buy” rating in a research report on Wednesday, October 30th. Needham & Company LLC boosted their target price on Stryker from $393.00 to $409.00 and gave the stock a “buy” rating in a research report on Wednesday, October 30th. Barclays boosted their target price on Stryker from $402.00 to $418.00 and gave the stock an “overweight” rating in a research report on Thursday, October 31st. Finally, Royal Bank of Canada boosted their target price on Stryker from $386.00 to $400.00 and gave the stock an “outperform” rating in a research report on Wednesday, October 30th. Five research analysts have rated the stock with a hold rating and sixteen have given a buy rating to the stock. Based on data from MarketBeat.com, Stryker currently has a consensus rating of “Moderate Buy” and an average price target of $393.65.

Stryker Trading Down 0.4 %

SYK opened at $388.14 on Friday. The stock has a market cap of $147.97 billion, a price-to-earnings ratio of 41.60, a P/E/G ratio of 2.93 and a beta of 0.91. The stock’s 50 day moving average price is $367.97 and its 200-day moving average price is $350.94. Stryker Co. has a one year low of $285.79 and a one year high of $398.20. The company has a debt-to-equity ratio of 0.66, a quick ratio of 1.22 and a current ratio of 1.91.

Stryker (NYSE:SYK) last released its earnings results on Tuesday, October 29th. The medical technology company reported $2.87 EPS for the quarter, beating analysts’ consensus estimates of $2.77 by $0.10. The firm had revenue of $5.49 billion for the quarter, compared to analysts’ expectations of $5.37 billion. Stryker had a return on equity of 23.07% and a net margin of 16.34%. The company’s quarterly revenue was up 11.9% on a year-over-year basis. During the same quarter in the prior year, the firm posted $2.46 earnings per share. On average, equities analysts forecast that Stryker Co. will post 12.06 EPS for the current year.

About Stryker

Stryker Corporation operates as a medical technology company. The company operates through two segments, MedSurg and Neurotechnology, and Orthopaedics and Spine. The Orthopaedics and Spine segment provides implants for use in total joint replacements, such as hip, knee and shoulder, and trauma and extremities surgeries.